Detection of TFPI2 methylation in the serum of colorectal cancer patients

Hibi, Kenji; Goto, Tetsuhiro; Shirahata, Atsushi; Shimada, Mitsuo; Kigawa, Gaku; Nemoto, Hiroshi; Yukitoshi, Sanada

doi:10.1016/j.canlet.2011.07.006

Cited by 86 publications

(87 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…50 Tissue factor pathway inhibitor 2 (TFPI2) methylation (7 of 73 samples; 10%) in serum from patients with GC was correlated significantly with lymph node metastasis. 51 In the current study, the level of RUNX3 methylation in serum, possibly caused by circulating nucleic acid released by GC cells, was correlated significantly with methylation in GC tissues (kappa statistic, 0.887). Among all GC tissues, including unmethylated samples, there was still a positive proportion of 70%; however, no RUNX3 methylation was detected in serum samples from patients who had benign lesions except for 2 patients who had severe dysplasia, which was considered early GC.…”

supporting

confidence: 49%

Stepwise cumulation of RUNX3 methylation mediated by Helicobacter pylori infection contributes to gastric carcinoma progression

Liu

et al. 2012

Cancer

View full text Add to dashboard Cite

BACKGROUND: Helicobacter pylori has been recognized as a definite carcinogen for gastric cancer (GC); however, the pathogenesis of H. pylori infection remains unclear. Runt-related transcription factor 3 (RUNX3) is a candidate tumor suppressor gene whose deficiency is causally related to GC. However, in H. pylori infection-associated GC, the role of RUNX3 has not been studied. METHODS: The authors used real-time methylation-specific polymerase chain reaction analysis to determine methylation status of the RUNX3 promoter in a spectrum of gastric lesions, including 220 samples of chronic atrophic gastritis, 196 samples of intestinal metaplasia, 134 samples of gastric adenoma, 102 samples of dysplasia, and 202 samples of GC with paired noncancerous mucosa tissues and corresponding blood specimens. The association of abnormal methylation with precancerous gastric lesions was evaluated along with the association between RUNX3 methylation and H. pylori infection, and the concordance of methylation levels was investigated between serum and tissues. RESULTS: The results indicated that increasing RUNX3 promoter methylation was correlated with distinct stages of GC progression. GC tissues had the highest methylation proportion (75.2%) compared with precancerous gastric lesions, including chronic atrophic gastritis (15.9%), intestinal metaplasia (36.7%), gastric adenoma (41.8%), and dysplasia (54.9%). H. pylori infection, a major risk factor for GC, contributed to the inactivation of RUNX3 in gastric epithelial cells through promoter hypermethylation. The levels of RUNX3 methylation in serum were in significant concordance with the methylation levels observed in GC tissues (P ¼ .887). CONCLUSIONS: The current findings supported RUNX3 methylation as a risk factors for the carcinogenesis of chronic atrophic gastritis with H. pylori infection and indicated that circulating RUNX3 methylation is a valuable biomarker for the detection of early GC.

show abstract

supporting

confidence: 49%

Stepwise cumulation of RUNX3 methylation mediated by Helicobacter pylori infection contributes to gastric carcinoma progression

Liu

et al. 2012

Cancer

View full text Add to dashboard Cite

show abstract

“…In contrast, the sensitivities for TMEFF2/HPP1 were similar in blood and stool samples [35,48]. The methylation status of TFPI2 was analyzed in blood and stool samples as well, but TFPI2 performs well as a marker only when using fecal DNA for the analysis [56,63]. These results suggest that each potential marker has to be tested in stool or blood samples to optimize its sensitivity and specificity.…”

Section: Stoolmentioning

confidence: 56%

Detection of DNA hypermethylation in remote media of patients with colorectal cancer: new biomarkers for colorectal carcinoma

Herbst

Kolligs

2012

Tumor Biol.

View full text Add to dashboard Cite

Colorectal cancer is the third most common cancer and a major cause of cancer-related mortality. The lifetime risk to develop colorectal cancer is 6% in the Western world, and one third of the affected people will ultimately die from this disease. Colorectal carcinomas develop slowly over a period of several years. Therefore, identifying people with precancerous lesions holds the potential to reduce the incidence and mortality of colorectal cancer. Apart from mutations and chromosomal imbalances, inactivation of tumor suppressor genes by DNA hypermethylation has been recognized as an important mechanism driving colorectal carcinogenesis. In recent years, screening tests have been developed that rely on the detection of DNA hypermethylation in remote media to identify people suffering from asymptomatic colorectal cancers at early stages. Apart from their diagnostic value, methylation markers hold the potential to be used as prognostic markers. Here, we summarize the recent development of DNA methylation markers for colorectal cancer in remote media with regard to their diagnostic and prognostic value.

show abstract

“…27 Besides, in patients with colorectal cancer, TFPI2 methylation was more frequently observed in the serum of those with large, poorly differentiated carcinoma, deep invasion, lymph node metastases, or distant metastases. 28 Recently, methylated TFPI2 DNA in serum was found to be strongly associated with metastatic melanoma and could be used as a biomarker of metastatic melanoma. 29 In our previous study, TFPI2 methylation in the serum of patients with HCC was also observed more frequently according to the progression of TNM stage, suggesting that TFPI2 methylation tended to be detected more easily in patients with advanced HCC and might be used to predict HCC prognosis.…”

Section: Discussionmentioning

confidence: 99%

Methylation of tissue factor pathway inhibitor 2 as a prognostic biomarker for hepatocellular carcinoma after hepatectomy

Sun

Fan

et al. 2016

J of Gastro and Hepatol

View full text Add to dashboard Cite

show abstract

Detection of TFPI2 methylation in the serum of colorectal cancer patients

Cited by 86 publications

References 11 publications

Stepwise cumulation of RUNX3 methylation mediated by Helicobacter pylori infection contributes to gastric carcinoma progression

Stepwise cumulation of RUNX3 methylation mediated by Helicobacter pylori infection contributes to gastric carcinoma progression

Detection of DNA hypermethylation in remote media of patients with colorectal cancer: new biomarkers for colorectal carcinoma

Methylation of tissue factor pathway inhibitor 2 as a prognostic biomarker for hepatocellular carcinoma after hepatectomy

Contact Info

Product

Resources

About